Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>Events>This Event
  Events - December 2013


Life Science R&D Big Data Leaders Forum

03 Dec 2013 - 05 Dec 2013 - Ramada Plaza Basel, Switzerland



Bookmark and Share


This 3 day forum is the “must attend” event for those senior decision-makers looking to make the shift towards big data and for those looking to improve their implementation of data-driven approaches for their specific departments.

The first day will feature several keynote presentations from C-Level thought leaders on big data in the R&D space and heads of major research institutions who are at the front-end of the big data challenge. They will be discussing the strategic drivers for big data and key implementation guidance on how to make best use of this approach.

Day 2&3 of the Forum will feature 3 specific streams depending on the phase of R&D that is most crucial for you:

-              Discovery & Translational Big Data Forum;

-              Clinical Data Management Forum;

-              Real-World & Health Outcomes Big Data Forum.

Discovery & Translational Big Data Forum will be focusing on important issues related to use of big data to support various functions within the drug discovery process, including better designing NMEs, re-engineering and re-initiating previously failed drug programs and will enable participants to make the most informed decisions possible on how to enhance the management and application of their discovery and translational data. Clinical Data Management Forum will explore a number of areas vital to the development of clinical data management (CDM) and present key issues in selecting and implementing a CDM system. Real-World & Health Outcomes Big Data Forum will discover how to best design observational studies to get most of the real world data generated, what are the new and innovative approaches to capture, store and manage as well as what is the role of evidence and health outcomes data in decision-making.

To request the full agenda please follow the link:

http://bigdata2013.nextlevelpharma.com/request-agenda

Erika Vavrovicova

Life science Big Data Leaders Forum

Tel: +421 232 660 382

Fax: +421 2 3301 0331
Email: erika@nextlevellifesciences.com

Visit: bigdata2013.nextlevelpharma.com



Further information
Scientific News
New Database for Sharing MS Clinical Trial Data
A new database containing nearly 2500 patient records from the placebo arms of nine multiple sclerosis (MS) clinical trials is now available for research by qualified investigators.
Study Finds Factors That May Influence Influenza Vaccine Effectiveness
Researchers at NIH have suggested that the long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited.
BMS’s Opdivo Clinical Trial Shows Promise
Safety profile of the combination regimen from CheckMate -069 was consistent with previously reported studies and adverse events were managed using established safety algorithms.
Treatment of Common Prostate Cancer
Researchers at UTSW have found that the prostate cancer treatments suppress immune response and may promote relapse.
Cancer Drug Could Treat Blood Vessel Deformities
A drug currently being trialled in cancer patients could also be used to treat an often incurable condition that can cause painful blood vessel overgrowths inside the skin.
Structure of Crucial Enzyme Identified
Researchers at UTSW have determined the atomic structure of an enzyme that plays an essential role in cell division and better treatment of cancer.
New Immunotherapy Trial for Type 1 Diabetes
The search for a treatment for Type 1 diabetes (T1D) - which affects over 400,000 people in the UK – will be stepped up with the start of a new phase one clinical trial at Guy’s Hospital in London.
Recruitment of First Patient in Clinical Study
Company has announced recruitment of first patient in clinical study assessing Visco-ease with Beatson Cancer Centre for the treatment of RIX.
Fighting Prostate Cancer
Identifying the most promising compounds which can be used as medications for prostate cancer.
Chi-Med Initiates Sulfatinib Phase III Registration Study
Company has initiated SANET-p, a Phase III registration trial of sulfatinib with pancreatic neuroendocrine tumors (“NETs”).
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!